Patents by Inventor Arnold Satterthwait

Arnold Satterthwait has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IDENTIFICATION OF COMPOUNDS THAT REGULATE APOPTOSIS
    Publication number: 20130157260
    Abstract: An assay for identifying compounds that affect conversion of Bcl-2 family protein from an antiapoptotic to a proapoptotic form or inhibit activity of Bcl-2 family protein is described.
    Type: Application
    Filed: December 2, 2010
    Publication date: June 20, 2013
    Applicant: Sanford-Burnham Medical Research Institute
    Inventors: Arnold Satterthwait, Xiao-kun Zhang, Xiuwen Zhu, Siva Kolluri, John C. Reed
  • METHODS OF REGULATING APOPTOSIS
    Publication number: 20100292145
    Abstract: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and related Bcl-2 family members are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing or preventing apoptosis are described, together with methods for identifying molecules that induce or prevent apoptosis through interaction with Bcl-2-family members. Methods for treatment of proliferative diseases and neurodegenerative diseases using the modulators of Bcl-2 and related family members are also disclosed.
    Type: Application
    Filed: June 15, 2010
    Publication date: November 18, 2010
    Applicant: Sanford-Burnham Medical Research Institute
    Inventors: Arnold Satterthwait, Xiao-kun Zhang, Xiuwen Zhu, Siva Kolluri
  • Compounds that regulate apoptosis
    Patent number: 7745574
    Abstract: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and related Bcl-2 family members are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing or preventing apoptosis are described, together with methods for identifying molecules that induce or prevent apoptosis through interaction with Bcl-2-family members. Methods for treatment of proliferative diseases and neurodegenerative diseases using the modulators of Bcl-2 and related family members are also disclosed.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: June 29, 2010
    Assignee: The Burnham Institute
    Inventors: Arnold Satterthwait, Xiao-kun Zhang, Xiuwen Zhu, Siva Kolluri
  • COMPOSITIONS AND METHODS FOR MODULATING NOD-LIKE RECEPTOR ACTIVITY AND USES THEREOF
    Publication number: 20100093623
    Abstract: Disclosed herein are compositions and methods relating to a peptide that inhibits Nod-like Receptors. Further provided are compositions and methods for treating or preventing inflammation, including diseases associated with inflammation such as inflammatory bowel disease, Crohn's disease, ulcerative colitis, arthritis, psoriasis, Alzheimer's disease, cardiovascular disease, diabetes, and sepsis.
    Type: Application
    Filed: July 16, 2009
    Publication date: April 15, 2010
    Applicant: Burnham Institute for Medical Research
    Inventors: John C. Reed, Benjamin Faustin, Arnold Satterthwait
  • Compounds that regulate apoptosis
    Publication number: 20070054863
    Abstract: Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and related Bcl-2 family members are identified. These compounds have the ability to convert the activity of Bcl-2-family member proteins from anti-apoptotic to pro-apoptotic. Methods for inducing or preventing apoptosis are described, together with methods for identifying molecules that induce or prevent apoptosis through interaction with Bcl-2-family members. Methods for treatment of proliferative diseases and neurodegenerative diseases using the modulators of Bcl-2 and related family members are also disclosed.
    Type: Application
    Filed: May 11, 2006
    Publication date: March 8, 2007
    Inventors: Arnold Satterthwait, Xiao-kun Zhang, Xiuwen Zhu, Siva Kolluri
  • Peptide drugs for chronic lymphocytic leukemia (CLL) and other cancers
    Publication number: 20060198832
    Abstract: The present invention provides a modified BAD peptide or peptidomimetic which includes an amino acid sequence having at least 60% amino acid identity with SEQ ID NO: 1, where the modified BAD peptide or peptidomimetic has enhanced affinity for Bcl-2 as compared to wild type BAD peptide (SEQ ID NO: 1). Further provided herein is a composition containing a delivery agent and a modified BAD peptide or peptidomimetic which includes an amino acid sequence having at least 60% amino acid identity with SEQ ID NO: 1, where the modified BAD peptide or peptidomimetic has enhanced affinity for Bcl-2 as compared to wild type BAD peptide (SEQ ID NO: 1).
    Type: Application
    Filed: November 3, 2005
    Publication date: September 7, 2006
    Inventors: Arnold Satterthwait, Xiuwen Zhu, Shinichi Kitada, John Reed